Enhertu plus Perjeta improved progression-free survival to 40.7 months versus 26.9 months with commonplace care in superior HER2-positive breast most cancers.Enhertu (fam-trastuzumab deruxtecan-nxki;...
Participation in a structured train program following remedy improved survival finish factors in superior CRC: inventory.adobe.com.The implementation of a 3-year structured train program...
Investigators evaluated remedy with Opdivo (nivolumab) plus Yervoy (ipilimumab) versus gemcitabine-carboplatin chemotherapy for beforehand untreated unresectable or metastatic urothelial carcinoma, in response to...
